

Original Article

In Vitro Effects of Metronidazole and Albendazole on *Giardia lamblia* Isolated from Iranian Patients

F Mohamadnezhad, *F Ghaffarifar, A Dalimi

Dept. of Parasitology, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran

(Received 28 Dec 2007; Accepted 08 Mar 2008)

Abstract

Background: The aim of the present study was to evaluate the effects of metronidazole and albendazole against clinical isolates of *Giardia lamblia* *in vitro*.

Methods: From all human samples of containing cysts, 10 isolates were successfully excysted *in vitro*. Trophozoites viability was assessed by eosine 0.1% and cultured axenically in TYI-S-33 modified medium supplemented with heat inactivated bovine serum 10%. All cultures were incubated in 37°C for 24-48 h. After this time trophozoites were exposed to different concentration (0.05, 0.1, 2, 10, 50 µg/ml) of drugs at 37° for 4 h. The IC₅₀ estimated between 0.1 and 10µg/ml for metronidazole and 0.062 and 0.1 µg/ml for albendazole.

Results: Eight isolates were found susceptible to the metronidazole while all isolates were found susceptible to the albendazole. Statistical results indicated that there was significant difference ($P<0.05$) in the sensitivity to metronidazole and albendazole in all isolates.

Conclusion: The killing affects of albendazole on *G.lamblia* was greater than metronidazole.

Keywords: *Giardia lamblia*, *Metronidazole*, *Albendazole*, *Susceptibility*, *In-Vitro*, *Iran*.

Introduction

Giardia lamblia, is a protozoan parasite in the intestine that causes extensive morbidity in the worldwide. Giardiasis is an important cause of chronic diarrhea and malabsorption. *Giardia* infects approximately 2% of the adults and 6 to 8% of the children in developed countries (1).

Despite the recognition of clinical illness in the last 40 years, there have been few reviews of therapy for this infection and no definitive effective treatment protocols have been published. In addition, only a handful of agents which are available may have adverse effects or be contraindicated in certain clinical situation. Also, resistance may play a role in some infections (1).

In human giardiasis, therapeutic failure is occurring more and more frequently, due to low compliance with drug therapy, reinfestation or parasite resistance to metronidazole and/or the nitroimidazole-related compounds secnidazole, tinidazole plus ornidazole as well as quinacrine and furazolidone. Albendazole has been proposed as an alternative to metronidazole but is not always effective (2-3).

G.lamblia has been reported to be highly susceptible to albendazole *in vitro*, but the efficacy of drugs in clinical studies is controversial (4).

There is an obvious need for alternative anti-giardial agents. The aim of the present study was to assess the effects of albendazole, metronidazole against *G.lamblia* trophozoites in *in vitro* condition.

*Corresponding author: Fax: +98-21-88013030,
E-mail: ghafarif@modares.ac.ir

Materials and Methods

Isolation of G.lamblia cysts

G.lamblia cysts were isolated from fresh feces of patients with giardiasis in Tehran. The samples showed no contamination to the other intestinal parasites and fungi. The average number of cysts was more than 10/40 field.

G.lamblia cysts were washed, purified and concentrated from feces using sucrose flotation method with a simplified sucrose gradient method. The cysts after being washed twice in distilled water were exposed with antibiotics and fungicide at 4°C for a maximum of 4 days prior to use (5).

The excystation procedure was done using Bingham & Meyer technique (6). These procedures involved two steps: the induction of excystation performed in acid solution, and the culture and axenization in TYI-S-33 medium supplemented with bile and heat inactivated bovine serum 10% for 24-48 h (6).

In excystation procedure 1 volume of clean cysts was added to 9 volumes of HCl in pH=2 and 0.01N, and were incubated at 37 °C for 1h (5).

Culture and count

For this experiment we needed to prepare a large number of trophozoites. Hence the excysted parasites were added into the culture tubes containing 7 ml of TYI-S-33 (borosilicae glass Screw-capped vials) and were incubated at 37 °C for 24-48 h. Trophozoites were harvested by chilling the tubes in ice water for 10-15 min. Then counted by haemocytometer (Neubauer cell-counter chamber). The optimum trophozoite concentration used was 50, 000 cells/ml (6).

Evaluation of parasite viability

To assess trophozoites viability, eosine 0.1% staining method was used.

Drugs assessment

Metronidazole and albendazole were prepared from Daru Paksh Co. The chemotherapeutic agents used were metronidazole and albendazole. Stocks solution of metronidazole and al-

bendazole were prepared in distilled water and dimethyl sulphoxide (DMSO) respectively. The final DMSO concentration in the culture tubes was always <0.5%. Different concentrations of each drug (0.05, 0.1, 2, 10, 50µg/ml) were prepared.

Trophozoites were exposed to different concentration (0.05, 0.1, 2, 10, 50 µg/ml) of the drugs at 37 °C for 4 h. After chilling in ice water, trophozoites were counted by haemocytometer. In control groups equivalent concentrations of distilled water and DMSO were used, in this regard we used water as the control for metronidazole group and DMSO (with the same concentration in stock solution) for albendazole group. The antiprotozoal activities of albendazole were compared with metronidazole within the same experiment.

Statistical analysis

The percentage of growth inhibition was calculated by comparison of growth rate of test group control group. The 50% inhibitory concentration (IC₅₀) was defined as the concentration of the drug that inhibited growth by 50% as calculated by probit analysis. The 90% inhibitory concentration (IC₉₀) was similarly calculated (7).

Results

From 37 human faecal samples containing *G. lamblia* cyst, 10 samples were excysted in axenic cultured successfully.

The IC₅₀ calculated for each isolate after 4 h drug exposure, is shown in Table1. For metronidazole IC₅₀ varied from 0.7 to 10 µg/ml representing a range of variation of 14.28 fold while IC₉₀ varied from 6 to 42.5 µg/ml representing a range of variation of 7.08 fold in susceptibility. For albendazole, the range of IC₅₀ varied from 0.062 to 0.1µg/ml representing a range of variation of 1.61 fold while IC₉₀ varied from 1.5 to 3µg/ml representing a range of variation of 2 fold in susceptibility.

The results of IC₅₀ in Table 1 showed that the mean for albendazole was 0.08 µg/ml and for

metronidazole was 3.32 µg/ml. In this regard, the ratio of drug concentration was 3.32/0.08 (41.5) and showed albendazole than to metronidazole 41.5 times more susceptible.

Table 2 shows the comparison of percentage of killed trophozoites of *G.lamblia* following 4h exposure to different concentrations of metronidazole and albendazole.

Table 1: Susceptibility of *G.lamblia* isolates to (metronidazole and albendazole) *in vitro* condition.

Isolate No.	IC ₅₀		IC ₉₀	
	Metronidazole (µg/ml)	Albendazole (µg/ml)	Metronidazole (µg/ml)	Albendazole (µg/ml)
1	2	0.065	13.5	1.55
2	4	0.095	20	2.3
3	1.5	0.065	10	1.5
4	9	0.1	42	2.4
5	1.4	0.08	14	1.6
6	1.8	0.078	20	2.4
7	0.7	0.063	6	1.5
8	2	0.1	20	3
9	10	0.1	42.5	2.4
10	0.8	0.062	7	1.47
Mean	3.32	0.08	19.5	2.01
S.D.	3.21	0.01	12.37	0.52
Variation(fold)	14.28	1.61	7.08	2

Table 2: Comparison of percentage of killed trophozoites of *G.lamblia* following 4h exposure to different concentration of metronidazole and albendazole

Drugs	Drug concentrations (µg/ml)	Percentage of killed trophozoites Following exposure to the drugs
Metronidazole	0.05	11
	0.1	32.3
	2	52.5
	10	75.8
	50	95.9
Albendazole	0.05	33
	0.1	60.4
	2	87
	10	100
	50	100

Discussion

The present study has demonstrated the superior potency of albendazole against *Giardia* trophozoites *in vitro* compared to metronidazole. Our finding was similar to the other reported data. Meloni *et al.* (1990) found that albendazole was 5-10 times more active than metronidazole or tinidazole against *G. lamblia* as judged the IC₅₀ (8). Edlind *et al.* (1990) reported that albendazole was 50 times more active than metronidazole (9). Upcroft *et al.* (1999) reported that a great deal of variation in the antiprotozoal efficacies of the 13 compounds tested was revealed. Only one compound was less effective than metronidazole against all three species of protozoa examined. All other compounds were as effective or more effective than metronidazole against some or all organisms tested (10). According to Upcroft *et al.* (2001) study the MIC for metronidazole susceptible lines was 6.3 µM in those assays and that for the resistant lines was consistently higher (11). Majewska *et al.* (1991), found that all individual stocks were composed of parasite populations characterized by significantly ($P<0.05$) differing sensitivities to both ornidazole and metronidazole (12). Farbey *et al.* (1995) reported that dose-response curves were constructed for each isolate for metronidazole, the most common clinically used anti-giardial agent, as well as for albendazole. Less than a 9-fold variation was found in the susceptibility of the isolates to albendazole, while for metronidazole there was well over a 16,000-fold variation between the same groups of isolates (13). In 2003 clinical resistance against the drug has been reported by Wright *et al.*, including cases where patients failed both metronidazole and albendazole treatments. Maintaining the usefulness of the existing drugs is the most cost-effective measure to ensure the continued availability of anti-giardial drugs (14). We found difference in activity of the drugs against various isolates. These differences

could be due to different strains of *G.lamblia*. The heterogeneity in drug sensitivity of parent *G.lamblia* populations may be one of the factors responsible for treatment failures of human giardiasis.

The results of this study are significant with respect to prospects for a new approach to the chemotherapy of giardiasis. Albendazole appears to be an ideal anti-giardial agent. It has lower toxicity than currently available chemotherapeutic agents and is relatively insoluble and poorly absorbed from the gut, thus maximizing contact with intestinal parasites and should not affect the intestinal flora.

Acknowledgements

This study was supported by Tarbiat Modares University through pecuniary aid. The authors wish to thank Mr. Poorghasem, Dr Farrahi from Danesh laboratory for kind cooperation and Miss Ghasemi and Mrs Jaberri for kind helping. The authors declare that there is no Conflict of Interests.

References

1. Gardner TB, Hill DR. Treatment of Giardiasis. *Clinic Microbiol Rev.* 2001;14(1): 114-28.
2. Cruz A, Sousa IM, Azeredo I. Isolation, excystation and axenization of *Giardia lamblia*:in vitro susceptibility to metronidazole and albendazole. *Antimicrob Agents Chemother.* 2003;51:1017- 20.
3. Lemee V, Zaharia I, Robodonirina M. Metronidazole and albendazole susceptibility of 11 clinical isolates of *Giardia duodenalis* from france. *J Antimicrob Chem.* 2000;46:819-21.
4. Cedillo-Rivera R, Munoz O. *In-vitro* susceptibility of *Giardia lamblia* to albendazole, mebendazole and other chemotherapeutic agents. *J Med Microbiol.* 199;37: 221-4.

5. Hautus M, Kortbeek L, Vetter J, Laarman J. *In vitro* excystation and subsequent axenic growth of *Giardia lamblia*. *Trans R Soc Trop Med Hyg.* 1988;82:858–61.
6. Schupp D, Januschka M, Sherlock⁴¹ Stibbs H, Meyer E, Bemrick W, Erlandsen SL. Production of viable *Giardia* cysts *in vitro*: determination by fluorogenic dye staining, excystation, and animal infectivity in the mouse and Mongolian gerbil. *Gastroenterology.* 1988;95:1–10.
7. Finney DL. Probit analysis. New York: Cambridge University Press; 1977.
8. Meloni BP, Thompson CA, Reynoldson JA, Seville P. Albendazole: a more effective anti-giardial agent *in vitro* than metronidazole or tinidazole. *Trans R Soc Trop Hyg.* 1990;84:375-379.
9. Edlind TD, Hang TL, Chakraborty PR. Activity of the antihelminthic benzimidazoles against *Giardia lamblia* *in vitro*. *J Infect Dis.* 1990;162:1408-1411.
10. Upcroft JA, Campbell RW, Benakli K, Upcroft P, Vanelle P. Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and-resistant *Giardia*, *Trichomonas*, and *Entamoeba* spp. *Antimicrob Agents Chemother.* 1999;43:73-76.
11. Upcroft JA, Upcroft P. Drug susceptibility testing of anaerobic protozoa. *Antimicrob Agents Chemother.* 2001;45(6):1810-1814.
12. Majewska AC, Kasprzak W, De Jonckheere F, Kaczmarek E. Heterogeneity in the sensitivity of stocks and clones of *Giardia* to metronidazole and ornidazole” *Trans Soc Trop Med Hyg.* 1991;85:67-9.
13. Farbey MD, Reynoldson JA, Thompson RC. *In vitro* drug susceptibility of 29 isolates of *Giardia duodenalis* from humans as assessed by an adhesion assay. *Int J Parasitol.* 1995;25(5):593-9.
14. Wright JM, Dunn LA, Upcroft P, Upcroft JA. Efficacy of anti-giardial drugs. *Expert Opinion on Drug Safety.* 2003;2(6):529-41.